Effects of the type 2 diabetes-associated PPARG P12A polymorphism on progression to diabetes and response to troglitazone. - Wikidata - awgldk - TriplyDB

Effects of the type 2 diabetes-associated PPARG P12A polymorphism on progression to diabetes and response to troglitazone.

Effects of the type 2 diabetes-associated PPARG P12A polymorphism on progression to diabetes and response to troglitazone.

http://www.wikidata.org/entity/Q36496755

about

The complex interplay of genetic and lifestyle risk factors in type 2 diabetes: an overview Gestational diabetes mellitus shares polymorphisms of genes associated with insulin resistance and type 2 diabetes in the Greek population Genetics of type 2 diabetes: pathophysiologic and clinical relevance A HapMap harvest of insights into the genetics of common disease Pharmacogenomics of Drug Response in Type 2 Diabetes: Toward the Definition of Tailored Therapies?Exercise training, genetics and type 2 diabetes-related phenotypes.The Pro12Ala variant at the peroxisome proliferator-activated receptor gamma gene and change in obesity-related traits in the Diabetes Prevention Program.The prevention of type 2 diabetes.Individualized therapy for type 2 diabetes: clinical implications of pharmacogenetic data.The genetic susceptibility to type 2 diabetes may be modulated by obesity status: implications for association studies.Improvements in glucose homeostasis in response to regular exercise are influenced by the PPARG Pro12Ala variant: results from the HERITAGE Family Study Susceptibility to type 2 diabetes mellitus--from genes to prevention Principles and practice of nonpharmacological interventions to reduce cardiometabolic risk.Pharmacogenomics of oral antidiabetic medications: current data and pharmacoepigenomic perspective.Clinical translation of genetic predictors for type 2 diabetes.Pharmacogenetics of Anti-Diabetes Drugs.Inherited destiny? Genetics and gestational diabetes mellitus.Pharmacogenomics and pharmacogenetics of thiazolidinediones: role in diabetes and cardiovascular risk factors.Effect of the PPARG2 Pro12Ala Polymorphism on Associations of Physical Activity and Sedentary Time with Markers of Insulin Sensitivity in Those with an Elevated Risk of Type 2 Diabetes Pharmacogenetics in type 2 diabetes: potential implications for clinical practice Meta-analysis of gene-environment interaction: joint estimation of SNP and SNP × environment regression coefficients.No interactions between previously associated 2-hour glucose gene variants and physical activity or BMI on 2-hour glucose levels.Association of type 2 diabetes susceptibility loci with one-year weight loss in the look AHEAD clinical trial Phenotyping, Etiological Factors, and Biomarkers: Toward Precision Medicine in Autism Spectrum Disorders.Genetic associations of leptin-related polymorphisms with systemic lupus erythematosus Use of genomic panels to determine risk of developing type 2 diabetes in the general population: a targeted evidence-based review.Pharmacogenomics in type II diabetes mellitus management: Steps toward personalized medicine.Genetic polymorphisms of peroxisome proliferator-activated receptors and the risk of cardiovascular morbidity and mortality in a community-based cohort in washington county, Maryland.Influence of SLCO1B1 and CYP2C8 gene polymorphisms on rosiglitazone pharmacokinetics in healthy volunteers PPAR Genomics and Pharmacogenomics: Implications for Cardiovascular Disease.A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycemic traits and insulin resistance Peroxisome proliferator-activated receptors as molecular targets in relation to obesity and type 2 diabetes.Pharmacogenetics of thiazolidinedione therapy.Pharmacogenetics of glucose-lowering drug treatment: a systematic review.Diabetes prevention: can insulin secretagogues do the job?Ordered stratification to reduce heterogeneity in linkage to diabetes-related quantitative traits.Computational Analysis of Single Nucleotide Polymorphisms Associated with Altered Drug Responsiveness in Type 2 Diabetes Pharmacogenetics: potential role in the treatment of diabetes and obesity PPARγ2 polymorphism and human health.Genetic architecture of type 2 diabetes: recent progress and clinical implications

P2860

Q26997813-C36D6225-AF08-475B-99C9-AC69847A4255 Q28284936-17731391-91C7-40FD-9E9F-FFDF1FFC5597 Q28302158-15E87C2C-F12E-4B6C-93C2-B7BC1C7928E3 Q29614875-ACE70B79-AEFF-43DA-9EEF-252C4A3D1DBC Q30388214-C54903A9-7EDB-4C5A-8235-CF5071658C41 Q30417635-30945322-B0B0-41F9-8106-D65B6A9EA82A Q30482667-ACDB1417-DBB4-421B-8C43-5D40F573E379 Q30484253-E7EA934D-A981-4F6D-B21E-DB14FC38BB99 Q30571118-73516396-B161-48E3-9E4C-DF8BD23C537A Q33337217-65E33995-D238-4405-AE59-EC8DC509F965 Q33735643-8B848429-F9DE-4ECA-8FA8-3938594D02F8 Q33759253-4A3D5A7A-22D4-47F5-A996-55D54775371E Q33793843-ED67A949-BFBB-4A1B-8267-6055E1FFB611 Q33993320-607D565C-7796-4269-A4CF-CE9DDCA48029 Q34124681-0E2EDAA9-54FA-42A4-95AC-F86397478608 Q34181995-EB222DE2-0FC5-4810-96D4-6407F0DA69BE Q34971477-E9CFF31E-661C-4DF9-9AB8-F082A82005E9 Q35039274-6D66EC37-59EC-4020-842D-0FFF2F31B2F5 Q35606921-581AA072-B69B-4984-9937-EFFFD1BBD143 Q35840645-7B831BD4-628C-40B8-8D9E-2651697080E2 Q35852977-DB841C0E-887B-49CD-8131-AD5FB23B490F Q35902855-2C6ECCAB-8A13-4315-9325-D29C9ACD4F77 Q36120556-B846B285-8578-4207-8820-493757AE5BF5 Q36146082-E48E02C0-6A25-45A8-B711-4A1E3FF0AAD2 Q36315896-EF9BDCB9-8374-465D-B7E4-635D4B907380 Q36384522-F6E036E0-743C-4AD0-8913-5EE30D28FA09 Q36441465-3B8D16B7-26D8-4CA4-AAED-269F749B9E7C Q36445100-360C91D1-5941-4013-816D-177D5451593A Q36475040-F5074F3C-FF0C-4DFA-8DE1-790A05BA4C8B Q36528512-AA8C83D3-39B7-407F-B5F0-5AD7B9FDBA73 Q36731268-A11E6B99-F92A-4C3B-B0D7-9AE4670C40A9 Q36845108-F0906B32-F01D-4034-B023-016DDF71D3BA Q36918107-29D1B493-55F6-4838-AC9A-6F4818A4815C Q36982648-5DF9BCA4-CA44-4136-B26F-DAB5A6D1EC02 Q37102832-3184C811-C2DA-4134-A856-1F07BAD5EE1C Q37105829-FB50A7AA-4A88-4F12-B3A4-40719309F186 Q37134345-6F2233C0-EEE1-4F96-8229-3043841D11B9 Q37142047-1BC87E2C-CF1A-496C-9CF0-286F8219D3E8 Q37159796-06255F5A-2EF6-40A4-A160-9BF8DFFC197C Q37189221-BB74F04B-DA61-47AD-BDFB-50692509D2E3

P2860

Effects of the type 2 diabetes-associated PPARG P12A polymorphism on progression to diabetes and response to troglitazone.

http://www.wikidata.org/entity/Q36496755

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年学术文章

@wuu

2007年学术文章

@zh-cn

2007年学术文章

@zh-hans

2007年学术文章

@zh-my

2007年学术文章

@zh-sg

2007年學術文章

@yue

2007年學術文章

@zh

2007年學術文章

@zh-hant

name

Effects of the type 2 diabetes ...... and response to troglitazone.

@ast

Effects of the type 2 diabetes ...... and response to troglitazone.

@en

type

label

Effects of the type 2 diabetes ...... and response to troglitazone.

@ast

Effects of the type 2 diabetes ...... and response to troglitazone.

@en

prefLabel

Effects of the type 2 diabetes ...... and response to troglitazone.

@ast

Effects of the type 2 diabetes ...... and response to troglitazone.

@en

P1433

Q36496755-414F29F5-668A-4C83-9F88-AF6EB72587DF

P1476

Q36496755-62355802-EF93-4610-9837-6FC634506247

P2093

Q36496755-0A389E85-6799-469A-BDDB-2BD9622E4512

Q36496755-2103A1E9-0AC3-4FDB-9B92-12E99BFD697B

Q36496755-49FAECF0-EF5E-4E16-AD84-7722FC00F2C1

Q36496755-89DA0BFF-6275-429B-91B5-BE26486126B0

Q36496755-A8E892EF-0FDD-4D6E-947D-7D8E639E314D

Q36496755-B5ABC63C-902F-4C0C-B8CF-D82AC39E4127

P2860

Q36496755-1379B897-CB19-4667-987C-6C62C1728A62

Q36496755-1D029216-88BB-4565-B21C-C467D6FC42F6

Q36496755-1EB990E3-7EC3-4D5F-A696-3F80FFFE0F51

Q36496755-221A46B5-8F0F-4E0C-B4DC-9D4CDE87C677

Q36496755-25A71638-090F-492A-81D3-6E61ABD7AE6D

Q36496755-291447D5-9176-48E6-88A3-C8B3309BF10D

Q36496755-30C7C0B5-AC60-4D03-ADBC-3D510284FE61

Q36496755-372CD151-F047-400A-84BA-ED44A6BC67B8

Q36496755-3C5F79E2-D042-4037-A482-D81076B4D181

Q36496755-3C7E7F26-5A3F-49E8-B932-B412D414076E

P304

Q36496755-622F72CA-41EC-4916-8752-884F6052A374

P31

Q36496755-DDD69AC3-1B4D-41D2-BEE3-7E61ED4D28BA

P356

Q36496755-1131B090-C41B-4516-97DB-57ABCD5C6BC2

P407

Q36496755-20051255-8BE8-478F-9538-64B9EA5FE3F1

P433

Q36496755-CB3BB114-7570-48A5-8B8F-CBE4A334D32B

P478

Q36496755-7554B835-C652-440F-98A7-190B35347AA6

P50

Q36496755-05E35120-4F07-4B9D-8F92-0E933282955B

Q36496755-628130A6-6C68-467C-8708-3F46651F1844

Q36496755-78CC47F9-6632-4FC0-ADA6-B35E016F5D6A

Q36496755-99B8098F-2C42-4C9B-B736-06ED50D33F4A

Q36496755-DFF8C7FB-FB95-45E3-B6CE-3922FF1CDBEC

P577

Q36496755-16EB5820-8BC1-4EA8-9CC7-F01DC3115570

P5875

Q36496755-250F3F3A-D11C-4C20-BA32-1ED64235678C

P698

Q36496755-6F3FBAF7-786D-4691-ABBB-FB14496ECD72

P921

Q36496755-D61A0C06-0FA6-453C-9A7D-B1D956DEB639

P932

Q36496755-AAF8290C-6B51-49AB-9719-82BACC7660B4

P356

P1433

The Journal of Clinical Endocrinology and Metabolism

P1476

Effects of the type 2 diabetes ...... and response to troglitazone.

@en

P2093

David M Nathan

http://www.w3.org/2001/XMLSchema#string

Jose C Florez

http://www.w3.org/2001/XMLSchema#string

Kathleen A Jablonski

http://www.w3.org/2001/XMLSchema#string

Maria W Sun

http://www.w3.org/2001/XMLSchema#string

Nick Bayley

http://www.w3.org/2001/XMLSchema#string

Richard F Hamman

http://www.w3.org/2001/XMLSchema#string

P2860

Genetic prediction of future type 2 diabetes

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

Assessing the impact of population stratification on genetic association studies

The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes

Implication of the Pro12Ala polymorphism of the PPAR-gamma 2 gene in type 2 diabetes and obesity in the French population.

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance

Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes

Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study

An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma)

P304

1502-1509

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1210/JC.2006-2275

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

92

http://www.w3.org/2001/XMLSchema#string

P50

Diabetes Prevention Program Research Group

David Altshuler

William C. Knowler

P577

2007-01-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6588670

http://www.w3.org/2001/XMLSchema#string

P698

17213274

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

P932

2267936

http://www.w3.org/2001/XMLSchema#string